The abstract is read at the publisher; the summary is JClub's.
An international expert panel updated consensus clinical trial response criteria for invasive fungal diseases, covering aspergillosis and other molds, invasive candidiasis, cryptococcosis, and dimorphic fungi.
- Why it matters: Existing 2008 consensus criteria may not reflect advances in diagnosis, management, and the growing at-risk patient population, making response categorization important for evaluating new therapies.
- What they did: The panel convened under ECMM and MSGERC to revise outcome evaluation guidelines, detailing methods, key changes, and next steps for adults and children across multiple mycoses.
- The result: The resulting manuscript provides updated criteria for defining study outcomes and assessing treatment responses, supporting more appropriate evaluation of antifungal interventions in clinical trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.